Abstract
Despite many improvements in thoracic surgery and oncology, the best treatment strategy for T4 non-small cell lung cancer(NSCLC) is yet to be identified. However, select patients without N2/N3 disease have been shown to be benefited from surgical resection. We aim to determine the impact of neoadjuvant chemotherapy and/or high-dose radiation therapy on survival in patients with T4N0-1 non-small cell lung cancer.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call